NCT00510016

Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 14 Days
• Healthy volunteers: Not accepted

Summary

To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.

Conditions

• Neonatal Abstinence Syndrome

Interventions

Type	Name	Description
DRUG	Clonidine HCL	Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm

Timeline

• Start date: 2002-07-01
• Completion: 2005-12-01
• First posted: 2007-08-01
• Last updated: 2017-01-11

Locations

1 site across 1 country: United States